AIDX

20/20 Biolabs, Inc. (AIDX) - Q2 2026 Filing Summary

Business Context and Reporting Period

This summary covers the Form 10-Q for the quarterly period ended June 30, 2026. 20/20 Biolabs, Inc. is an emerging growth company developing AI-powered laboratory blood tests for early cancer detection (OneTest) and chronic disease prevention. The company operates a CLIA-accredited laboratory in Gaithersburg, MD, and recently completed a direct listing on Nasdaq. The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Q2 2026 revenue increased 36.5% year-over-year to $730,571, driven primarily by a 47.1% increase in OneTest sales due to Maryland firefighter cancer screening grants. Conversely, BioCheck revenue declined 15.3% and CLIAx revenue dropped to zero for the quarter.
• Expense Expansion: Operating expenses increased significantly. Sales, General, and Administrative (SG&A) expenses rose 58.5% to $1.29 million, attributed to public company costs, executive compensation, and investor relations. R&D expenses increased 32.7% to $257,632 due to the development of the "OneTest for Longevity" product.
• Capital Structure Transformation: All outstanding Series A through D preferred stock was converted to common stock in February 2026. The company raised $6.0 million in Series E convertible preferred stock and converted all outstanding convertible notes payable into equity or Series E stock, eliminating current and long-term convertible debt liabilities.
• Non-Cash Charges: Net loss attributable to common stockholders was significantly impacted by a $1.12 million deemed dividend resulting from the modification of warrant exercise prices (reduced to $2.25) and $121,662 in accrued Series E preferred dividends.

Outlook, Risks, and Management Commentary

• Liquidity: Management anticipates continued operating losses in the near term. However, the company raised $6 million in private placements and $250,000 in convertible debt during the period, resulting in a cash balance of $4.5 million. Management believes this is sufficient to fund operations for at least the next 12 months, though future capital raises may be necessary.
• Strategic Initiatives: The company launched "OneTest for Longevity" in February 2026. A standstill agreement was entered into with Streeterville Capital, LLC (July 2026), restricting the conversion of Series E preferred stock into common stock unless the share price exceeds the Nasdaq minimum price by 10%.
• Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding the lack of sufficient trained professionals for risk assessment, accounting policies, and complex transaction valuation. Remediation efforts are underway.
• Risks: Key risks include the need for additional capital, the ability to maintain Nasdaq listing standards, and the dilution impact of the Series E preferred stock and outstanding warrants (3.66 million warrants outstanding).

Investor Verification Checklist

• Series E Preferred Stock Terms: Verify the liquidation preference ($6.27 million total) and the 9% annual preferred return (compounding daily), which accrues as a liability or mezzanine equity and impacts common equity value.
• Warrant Dilution: Confirm the impact of 3.66 million outstanding warrants with an exercise price of $2.25 (post-amendment) on future share count and EPS.
• Revenue Concentration: Assess reliance on the Maryland firefighter grant program for OneTest revenue growth, which drove the Q2 increase.
• Internal Control Remediation: Monitor progress on hiring qualified accounting personnel and formalizing controls to address the disclosed material weaknesses.
• Standstill Agreement: Review the terms of the July 2026 standstill agreement with Streeterville to understand constraints on share conversion and potential market volatility.